Hemophilia A trials in Sweden: Trial Insights

Filters: Condition: Hemophilia A Country / region: Sweden Clear all

61 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	1
2001	2
2002	2
2003	1
2004	1
2005	2
2006	2
2008	2
2009	5
2010	3
2011	3
2012	4
2013	3
2014	3
2015	3
2016	2
2017	4
2018	4
2019	2
2020	3
2021	2
2022	2
2023	2
2024	1
2025	2

Trials by status
Category	Trials
Completed	46
Active, not recruiting	8
Recruiting	4
Terminated	2
Unknown status	1

Top lead sponsors
Category	Trials
Novo Nordisk A/S	9
Baxalta now part of Shire	8
Swedish Orphan Biovitrum	8
Pfizer	6
Bayer	5
Bioverativ, a Sanofi company	3
Skane University Hospital	3
Bioverativ Therapeutics Inc.	2
Lund University	2
National Cancer Institute (NCI)	2

Top conditions
Category	Trials
Hemophilia A	61
Hemophilia B	13
Blood Coagulation Disorders	5
Coagulation Protein Disorders	4
Hemorrhage	4
Genetic Diseases, Inborn	2
Hematologic Diseases	2
Hemorrhagic Disorders	2
Lymphoma, Follicular	2
von Willebrand Diseases	2

Trials

Showing 51 to 61 of 61. Each trial links to its page on Pharma Observatory.

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery NCT00357656Phase 4CompletedBaxalta now part of ShireStarted 2006
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery NCT00243659Phase 3CompletedWyeth is now a wholly owned subsidiary of PfizerStarted 2006
Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A NCT00141843Phase 3CompletedWyeth is now a wholly owned subsidiary of PfizerStarted 2005
Genetic Susceptibility to Factor VIII Inhibitors NCT00344435ObservationalCompletedNational Cancer Institute (NCI)Started 2005
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients NCT00157157Phase 3CompletedBaxalta now part of ShireStarted 2004
Hemophilia Inhibitor Genetics Study (HIGS) NCT00166387ObservationalCompletedSkane University HospitalStarted 2003
International PMS Study - KOGENATE Bayer NCT00864552ObservationalCompletedBayerStarted 2002
The Malmö International Brother Study (MIBS) NCT00231751ObservationalCompletedSkane University HospitalStarted 2002
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 NCT00157053Phase 2/3CompletedBaxalta now part of ShireStarted 2001
The Second Multicenter Hemophilia Cohort Study NCT00341705ObservationalCompletedNational Cancer Institute (NCI)Started 2001
The FEIBA NovoSeven Comparative Study NCT00166309Not applicableCompletedSkane University HospitalStarted 2000

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa NCT06716814Status changeRecruiting to Active, not recruitingOctober 22, 2026
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa NCT06716814Enrollment change104 to 89October 22, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory